Select your languague:
Buy Xenical online from EU registered pharmacies


What is Xenical?

Xenical (orlistat) is a drug used to help people lose weight. This acts by preventing some of the fat elements of the food you eat from being absorbed into the body. Together with a reduced-calorie diet this can be a powerful ally. Check out more about Xenical below.

When is Xenical used?

You can find Xenical in both prescription and non-prescription forms. This drug combined with a weight-loss program is simply one of the best nowadays. If you are facing a complicated situation regarding your weight then you may be given the prescription form of Xenical. This is because you might have issues like high cholesterol and blood pressure, diabetes or heart disease. Xenical is often used after the you lost weight in order to prevent you from gain it again. Lipase inhibitors like Xenical act by blocking fat from being absorbed by the intestines. This will then be expelled from the body in the stool.

How to use Xenical?

Xenical capsules (120 mg) are taken orally up to three times per day along with a meal. The capsule can be taken up to one hour after finishing the meal. If your meal is light or it it simply does not contain fat in it, you can ignore it that time. Always follow your doctors instructions and do not exceed your intake. If you are taking Xenical, please avoid foods with more 30% fat. Also, please control your portions of meat (up to 85 grams) poultry and fish with each serving. Follow all advices from your medical professional. The intake of carbohydrates, fats and proteins should be evenly spread over three main meals. If you have one meal high in fat rather than spreading it over the course of the day, you may experience some side effects while on Xenical. This is why having a solid diet plan before you start taking the Xenical is vital in order for the drug to act properly and assist you reducing weight. Please talk to your doctor to get all the information and advice. Xenical will block the absorption of fat and some fat-soluble vitamins, so the intake of daily supplements to replace these essential vitamins is advised.


The usual dosage of Xenical for an adult is 120mg three times per day with or shortly after a main meal which has fat included in it. Do not take more than 120mg with a meal. This will not help you to lose more weight and may in fact cause side effects.

       Treatment Dosage Quantity Per Pill Price Buy now
Xenical Xenical 120mg 42 £2.38 £100.00 Buy Now
Xenical Xenical 120mg 84 £1.48 £124.70 Buy Now
Xenical Xenical 120mg 168 £1.36 £229.00 Buy Now
Xenical Xenical 120mg 252 £1.25 £315.00 Buy Now

*Prices are subject to change due to fluctuations and may differ from the price shown for the item on the product detail page. Items in your shopping cart will always reflect the recent and final price.

Buy Xenical With an Online Prescription

An online doctor consultation means filling out a medical questionnaire. A registered EU doctor assesses your medical questionnaire and analize whether Xenical is suitable and safe for you to buy. After approval, a prescription is issued and send to the registered EU pharmacy. You will receive your discretely shipped Xenical pills within 3 business days.

After several studies about the effect of Xenical/Orlistat, the results proved that Xenical helps losing loss. The results were higher than the placebo group. Xenical users lost an average of 3.4 kilos of body weight.

Orlistat Weight Loss Pill Review


Xenical is a specific inhibitor of gastrointestinal lipases with a long-lasting effect. Its therapeutic effect is carried out in the lumen of the stomach and small intestine and consists in the formation of a covalent bond with the active serine region of the gastric and pancreatic lipases. In this case, an inactivated enzyme loses its ability to break down food fats in the form of triglycerides into absorbable free fatty acids and monoglycerides. Since undigested triglycerides are not absorbed, the resulting decrease in calorie intake leads to a decrease in body weight. Thus, the therapeutic effect of the drug is carried out without absorption into the systemic circulation.

Judging by the results of the fat content in feces, the effect of orlistat begins 24–48 hours after ingestion. After discontinuation of the drug, the fat content in feces after 48–72 hours usually returns to the level that occurred before the start of therapy.


  • Suction- In volunteers with normal body weight and obesity, the systemic effect of the drug is minimal. 8 hours after oral administration of the drug, unchanged orlistat in plasma could not be determined, which means that its concentrations are below the level of 5 ng/ml.
    In general, after administration of therapeutic doses, unchanged orlistat in plasma was detected only in rare cases, while its concentrations were extremely small (<10 ng / ml or 0.02 μmol). There were no signs of cumulation, this confirms that the absorption of the drug is minimal.
  • Distribution- The volume of distribution cannot be determined since the drug is very poorly absorbed. In vitro, orlistat is more than 99% bound to plasma proteins (mainly lipoproteins and albumin). In minimal amounts, orlistat can penetrate red blood cells.
  • Metabolism- Judging by the data obtained in the animal experiment, the metabolism of orlistat is carried out mainly in the intestinal wall. In a study in obese people, it was found that approximately 42% of the minimal fraction of the drug that undergoes systemic absorption is accounted for by two main metabolites - M1 (four-membered hydrolyzed lactone ring) and M3 (M1 with cleaved N-formyl leucine residue).
    Molecules M1 and M3 have an open β-lactone ring and extremely weakly inhibit lipase (1000 and 2500 times weaker, respectively, than orlistat). Given such a low inhibitory activity and low plasma concentrations (on average 26 and 108 ng / ml, respectively) after taking therapeutic doses, these metabolites are considered pharmacologically inactive.
  • Breeding- Studies in individuals with normal and overweight have shown that the main route of elimination is the elimination of non-absorbable drug with feces. With feces, about 97% of the accepted dose of the drug was excreted, with 83% in the form of unchanged orlistat.
    The total renal excretion of all substances structurally associated with orlistat is less than 2% of the dose taken. The time to complete elimination of the drug from the body (with feces and urine) is 3-5 days. The ratio of orlistat excretion routes in volunteers with normal and overweight was the same. Both orlistat and metabolites M1 and M3 may be excreted with bile.
  • Pharmacokinetics in special clinical groups- Plasma concentrations of orlistat and its metabolites (M1 and M3) in children do not differ from those in adults when comparing the same doses of the drug. Daily excretion of fat with feces amounted to 27% of food intake during orlistat therapy and 7% when taking a placebo.

Indications of the drug Xenical

Long-term treatment of patients with obesity or patients with overweight, including having risk factors associated with obesity, in combination with a moderately hypocaloric diet;

in combination with hypoglycemic drugs (metformin, sulfonylurea derivatives and/or insulin) or a moderately hypocaloric diet in patients with type 2 diabetes who are overweight or obese.


Hypersensitivity to the drug or any other components contained in the capsule; chronic malabsorption syndrome; cholestasis.

Pregnancy and lactation

In studies of reproductive toxicity in animals, the teratogenic and embryotoxic effect of the drug was not observed. In the absence of a teratogenic effect in animals, a similar effect in humans should not be expected. However, due to the lack of clinical data, Xenical should not be prescribed to pregnant women.

Excretion of orlistat with breast milk has not been studied, therefore, it should not be taken during breastfeeding.

Side effects

The following categories are used to describe the frequency of adverse reactions: very often (≥1 / 10), often (≥1 / 100, <1/10), infrequently (≥1 / 1000, <1/100), rarely (≥1 / 10000 , <1/1000) and very rarely (<1/10000), including isolated cases.

Adverse reactions to orlistat occurred mainly from the gastrointestinal tract and were due to the pharmacological action of the drug, which prevents the absorption of food fats. Very often, phenomena such as oily discharge from the rectum, gas with a certain amount of discharge, imperative urges to defecate, steatorrhea, increased frequency of bowel movements, loose stools, flatulence, abdominal pain or discomfort were noted.

Their frequency increases with increasing fat content in food. Patients should be informed about the possibility of adverse reactions from the gastrointestinal tract and taught how to eliminate them by better dieting, especially in relation to the amount of fat contained in it. The use of a low-fat diet reduces the likelihood of side effects from the gastrointestinal tract and thereby helps patients to control and regulate fat intake.

As a rule, these adverse reactions are mild and transient. They occurred in the early stages of treatment (in the first 3 months), and most patients had no more than one episode of such reactions.

In the treatment of Xenical, the following adverse events from the gastrointestinal tract often occur “soft” stools, pain or discomfort in the rectum, fecal incontinence, bloating, tooth damage, gum disease.

It was also noted very often - headaches, upper respiratory tract infections, flu; often - lower respiratory tract infections, urinary tract infections, dysmenorrhea, anxiety, weakness.

Rare cases of allergic reactions are described, the main clinical symptoms of which were itching, rash, urticaria, angioedema, bronchospasm, and anaphylaxis.

Very rare cases of a bullous rash, an increase in the activity of transaminases and alkaline phosphatase, as well as individual, possibly serious, cases of the development of hepatitis,  are described (a causal relationship with Xenical or pathophysiological development mechanisms have not been established).

With the simultaneous appointment of Xenical and anticoagulants, there have been cases of a decrease in prothrombin, an increase in MNO.

Cases of rectal bleeding, diverticulitis, pancreatitis, and cholelithiasis have been reported (frequency of occurrence unknown).

In patients with type 2 diabetes mellitus, the nature and frequency of adverse events were comparable to those in individuals without diabetes with overweight and obesity. The only new side effects that occurred with a frequency of> 2% and ≥1% compared with placebo were hypoglycemic conditions (which could result from improved compensation for carbohydrate metabolism) and bloating.


There was no interaction with amitriptyline, atorvastatin, biguanides, digoxin, fibrates, fluoxetine, losartan, phenytoin, oral contraceptives, phentermine, pravastatin, warfarin, nifedipine GITS (gastro-intestinal therapeutic system) and nifedipine slow-release, sibutramine or alcohol (based on drug interaction studies). However, it is necessary to monitor the performance of MNO with concomitant therapy with warfarin or other oral anticoagulants.

With simultaneous administration with Xenical, a decrease in the absorption of vitamins A, D, E, K, and beta-carotene was noted. If multivitamins are recommended, they should be taken at least 2 hours after taking Xenical or at bedtime.

With the simultaneous administration of Xenical and cyclosporine, a decrease in plasma concentrations of cyclosporine was noted, therefore, a more frequent determination of plasma cyclosporine concentrations with the simultaneous administration of cyclosporine and Xenical is recommended.

When prescribing amiodarone during Xenical therapy, a decrease in the systemic exposure of amiodarone and desethylamiodarone was noted (by 25-30%), however, due to the complex pharmacokinetics of amiodarone, the clinical significance of this phenomenon is not clear. The addition of Xenical to long-term therapy with amiodarone may possibly lead to a decrease in the therapeutic effect of amiodarone.

The simultaneous administration of Xenical and acarbose should be avoided due to a lack of pharmacokinetic studies.

Dosage and administration

Inside, for adults - 1 capsule. (120 mg) with each main meal (during, or no later than 1 hour after a meal). If you skip a meal or the food does not contain fat, you can also skip a meal.

An increase in the dose of orlistat over the recommended (120 mg 3 times a day) does not lead to an increase in its therapeutic effect. Dose adjustment in elderly patients is not required. Dose adjustment for impaired liver or kidney function is not required. The safety and effectiveness of Xenical in children under the age of 18 have not been established.


In clinical studies in individuals with normal body weight and obese patients, single doses of 800 mg or multiple doses of 400 mg 3 times a day for 15 days were not accompanied by the appearance of significant adverse events. In addition, there is experience with the use of orlistat at 240 mg 3 times a day for 6 months in obese patients, which was not accompanied by a significant increase in the frequency of adverse events.

Symptoms: in cases of overdose, either the absence of adverse events was reported, or adverse events did not differ from those observed when taking the drug in therapeutic doses.

Treatment: in case of a severe overdose of Xenical, it is recommended to observe the patient for 24 hours.

According to studies in humans and animals, any systemic effects that could be associated with the lipase-inhibiting properties of orlistat should be quickly reversible.

Special instructions

Xenical is effective in terms of long-term control of body weight (reduction of body weight and its maintenance at a new level, prevention of repeated weight gain). Xenical treatment improves the profile of risk factors and diseases associated with obesity, including hypercholesterolemia, type 2 diabetes mellitus (NIDDM), impaired glucose tolerance, hyperinsulinemia, arterial hypertension, and a decrease in visceral fat.

When used in combination with hypoglycemic drugs such as metformin, sulfonylureas and / or insulin derivatives in patients with type 2 diabetes mellitus (BMI ≥28 kg / m 2 ) or obesity (BMI ≥30 kg / m 2 ) Xenical, in combination with a moderately hypocaloric diet, provides an additional improvement in the compensation of carbohydrate metabolism.

In clinical trials in most patients, the concentrations of vitamins A, D, E, K and beta-carotene during the course of two full years of orlistat therapy remained within the normal range. To ensure adequate intake of all nutrients, multivitamins can be prescribed.

The patient should receive a balanced, moderately hypocaloric diet containing no more than 30% nutritional value in the form of fats. A diet rich in fruits and vegetables is recommended. The daily intake of fats, carbohydrates, and proteins must be divided into three main methods.

The likelihood of adverse reactions from the gastrointestinal tract may increase if Xenical is taken against a diet rich in fats (for example, 2000 kcal/day, of which more than 30% is in the form of fats, which equals approximately 67 g of fat). Daily intake of fats should be divided into three main doses. If Xenical is taken with foods very rich in fat, the likelihood of gastrointestinal reactions increases.

In patients with type 2 diabetes mellitus, a decrease in body weight during treatment with Xenical is accompanied by an improvement in the compensation of carbohydrate metabolism, which may allow or require a reduction in the dose of hypoglycemic drugs.